Why the study?
Do drugs inhibiting the renin-angiotensin system as second-line therapy reduce systolic and diastolic blood pressure in hypertensive patients?
Do drugs inhibiting the renin-angiotensin system as second-line therapy reduce systolic and diastolic blood pressure in hypertensive patients?
This is a protocol for a Cochrane Review to evaluate the blood pressure lowering efficacy of RAS inhibitors as second-line therapy for primary hypertension.
Upcoming Cochrane synthesis will clarify RAS inhibitor role as second-line therapy; leaves open current recommendations for add-on hypertension treatment.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Primary objective: To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of drugs inhibiting the renin‐angiotensin system (RAS) as a second‐line drug in hypertensive patients. Secondary objectives: 1. To determine the effects of second‐line RAS inhibitor on variability of blood pressure. 2. To determine the effects of second‐line RAS inhibitor on pulse pressure. 3. To quantify the effect of second‐line RAS inhibitor on heart rate. 4. To quantify the effect of second‐line RAS inhibitor on withdrawals due to adverse effects.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: